Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Journal

Published

Jul 25, 2011

DOI

Save

Tip

Document

Download

Flag content

Tip

Save

Document

Download

Flag content

Abstract

This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.